Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation
Yu Chen, Ira Tandon, William J. Heelan, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 13, pp. 5330-5350
Open Access | Times Cited: 135

Showing 1-25 of 135 citing articles:

Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 165
Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors
Chunrong Yang, Yuchen Yang, Yujie Li, et al.
Journal of the American Chemical Society (2022) Vol. 145, Iss. 1, pp. 385-391
Closed Access | Times Cited: 86
Trends in Molecular Properties, Bioavailability, and Permeability across the Bayer Compound Collection
Daniel H. O’Donovan, Claudia De Fusco, Lara Kuhnke, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2347-2360
Closed Access | Times Cited: 51
Aptamer-Based Targeted Protein Degradation
Yuan Liu, Xu Qian, Chunyan Ran, et al.
ACS Nano (2023) Vol. 17, Iss. 7, pp. 6150-6164
Open Access | Times Cited: 45
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 26
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 22
Nano-PROTACs: state of the art and perspectives
Jie Zhong, Ruiqi Zhao, Yuji Wang, et al.
Nanoscale (2024) Vol. 16, Iss. 9, pp. 4378-4391
Closed Access | Times Cited: 18
PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer
Kailee A. Rutherford, Kirk J. McManus
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 4, pp. 454-463
Open Access | Times Cited: 17
Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
Qiao‐Hong Chen, Erick Munoz, Dennis Ashong
Cancers (2024) Vol. 16, Iss. 3, pp. 663-663
Open Access | Times Cited: 15
BRD4-targeted photodegradation nanoplatform for light activatable melanoma therapy
Shiman Lu, Zhaoqing Shi, Chendi Ding, et al.
Biomaterials (2025) Vol. 317, pp. 123101-123101
Closed Access | Times Cited: 2
Chemically engineering cells for precision medicine
Yixin Wang, Zhaoting Li, Fanyi Mo, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 3, pp. 1068-1102
Closed Access | Times Cited: 40
Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy
Weishan Wang, Chenghong Zhu, Bin Zhang, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 30, pp. 16642-16649
Closed Access | Times Cited: 39
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Jin Li, Xinxin Chen, Aiping Lü, et al.
The Innovation (2023) Vol. 4, Iss. 3, pp. 100413-100413
Open Access | Times Cited: 35
Nano Proteolysis Targeting Chimeras (PROTACs) with Anti‐Hook Effect for Tumor Therapy
Ni‐Yuan Zhang, Da‐Yong Hou, Xingjie Hu, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 37
Closed Access | Times Cited: 35
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Small-Molecule Ferritin Degrader as a Pyroptosis Inducer
Yu Chen, Wen Li, S. Chul Kwon, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 17, pp. 9815-9824
Closed Access | Times Cited: 32
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 27
The rise of degrader drugs
Mingxing Teng, Nathanael S. Gray
Cell chemical biology (2023) Vol. 30, Iss. 8, pp. 864-878
Open Access | Times Cited: 27
Recent Studies and Progress in the Intratumoral Administration of Nano-Sized Drug Delivery Systems
Wan Su Yun, Soo Hyun Kim, Dong-Kwon Lim, et al.
Nanomaterials (2023) Vol. 13, Iss. 15, pp. 2225-2225
Open Access | Times Cited: 27
Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy
Qi He, Liming Zhou, D.P. Yu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10458-10472
Closed Access | Times Cited: 26
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Xiang Li, Qian Liu, Xin Xie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1700-1711
Closed Access | Times Cited: 23
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy
Zhifeng Zou, Lei Yang, Hui-Jun Nie, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 8, pp. 1740-1751
Closed Access | Times Cited: 13
Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders
Ming Yang, Hua Xiang, Guoshun Luo
Biochemical Pharmacology (2024) Vol. 224, pp. 116246-116246
Closed Access | Times Cited: 12
PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review
Chao Wang, Yujing Zhang, Wanpeng Yu, et al.
International Journal of Biological Macromolecules (2024) Vol. 261, pp. 129864-129864
Closed Access | Times Cited: 9
Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
Yujeong Moon, Seong Ik Jeon, Man Kyu Shim, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 411-411
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top